Vetemex vet.

1 x 10 ml

Liquid for injection, solution

Active substance

Maropitant (Maropitant Citrate) : 10 mg/ml

ATC code

QA04AD90 Maropitant

QA04AD Other antiemetics

QA04A Antiemetics and antinauseants

QA04 Antiemetics and antinauseants

QA Alimentary tract and metabolism

Species

Dogs and cats.

Indications

Dogs

For the treatment and prevention of nausea induced by chemotherapy.

For the prevention of vomiting except that induced by motion sickness.

For the treatment of vomiting, in combination with other supportive measures. For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.

Cats

For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.

For the treatment of vomiting, in combination with other supportive measures.

Dose to be administered and administration route

For subcutaneous or intravenous use in dogs and cats.

The veterinary medicinal product solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant / kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days. Intravenous administration of the veterinary medicinal product should be given as a single bolus without mixing the product with any other fluids.

To prevent vomiting, the veterinary medicinal product solution for injection should be administered more than 1 hour in advance. The duration of effect is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.

As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.

For administration by subcutaneous injection, see also “special precautions for use in animals” (section 4.5).

Adverse reactions

Dogs:
Frequency	Adverse event
Common	Injection site pain*
(1 to 10 animals / 100 animals treated):
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylactic-type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) Neurological disorders such as ataxia, convulsion/seizure or muscle tremor; lethargy

* when injected subcutaneously

Cats:
Frequency	Adverse event
Very common (>1 animal / 10 animals treated)	Injection site pain*
(<1 animal / 10,000 animals treated, including isolated reports):	Anaphylactic-type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) Neurological disorders such as ataxia, convulsion/seizure or muscle tremor; lethargy

* when injected subcutaneously: moderate to severe response to injection (in approximately one third of cats)

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder, or its local representative, or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.